Browsing by Author Clements, Arthur

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 9 of 9
Issue DateTitleAuthor(s)Citation
2014Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinibAnforth, Rachael; Clements, Arthur; Fernandez Penas, Pablo; Kefford, Richard (Rick); Long, Georgina; Nguyen, Bao; Liu, Michael; Uribe, Pablo; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Nepean Clinical School: MedicineAcneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib, The Australasian Journal of Dermatology, vol.55, 4, 2014,pp 250-254
2015Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic MelanomaCarlino, Matteo; Chan, Matthew; Clements, Arthur; Kefford, Richard (Rick); Manolios, Nicholas; Western Clinical School: Medicine (Westmead); Northern Clinical School: Melanoma Institute of Australia; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Medicine (Westmead)Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma, Journal of Immunotherapy, vol.38, 1, 2015,pp 37-39
2013BRAF inhibitor activity in V600R metastatic melanomaClements, Arthur; Kefford, Richard (Rick); Long, Georgina; O'Toole, Sandra; Klein, Oliver; Menzies, Alexander; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: PathologyBRAF inhibitor activity in V600R metastatic melanoma, European Journal of Cancer, vol.49, 5, 2013,pp 1073-1079
2015Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeksAnforth, Rachael; Carlos, Giuliana R M; Clements, Arthur; Fernandez Penas, Pablo; Kefford, Richard (Rick); Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium InstituteCutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks, British Journal of Dermatology, vol.172, 1, 2015,pp 239-243
2015Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic MelanomaAnforth, Rachael; Carlino, Matteo; Carlos, Giuliana R M; Clements, Arthur; Fernandez Penas, Pablo; Menzies, Alexander Maxwel; Chou, Shaun; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Central Clinical School: MedicineCutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma, JAMA Dermatology, vol.151, 10, 2015,pp 1103-1109
2012Evidence for Therapeutic Drug Monitoring of Targeted Anticancer TherapiesClements, Arthur; Gao, Bo-Fu; Gurney, Howard; Balakrishnar, Bavanthi; WONG, Mark; Yeap, S; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead)Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies, Journal of Clinical Oncology, vol.30, 32, 2012,pp 4017-4025
2014Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanomaClements, Arthur; Haydu, Lauren; Kefford, Richard (Rick); Lee, Clara; Long, Georgina; Menzies, Alexander Maxwel; Azer, Mary; Western Clinical School: Medicine (Westmead); Central Clinical School: Surgery; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Central Clinical School: The Sydney Cancer Centre; Central Clinical School: MedicineFeatures and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma, Melanoma Research, vol.24, 5, 2014,pp 468-474
2015Ipilimumab-induced hypophysitis in melanoma patients: An Australian case seriesCarlino, Matteo; Chan, Matthew; Chipps, David; Chua, Elizabeth; Clements, Arthur; Kefford, Richard (Rick); Long, Georgina; Sweeting, Arianne; De Sousa, Sunita; Lam, T; Tonks, Katherine; Western Clinical School: Medicine (Westmead); Northern Clinical School: Melanoma Institute of Australia; Western Clinical School: Medicine (Westmead); Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; School of Public Health: Public HealthIpilimumab-induced hypophysitis in melanoma patients: An Australian case series, Internal Medicine Journal, vol.45, 10, 2015,pp 1066-1073
2014The nature and management of metastatic melanoma after progression on braf inhibitors: Effects of extended BRAF inhibitionChan, Matthew; Clements, Arthur; Guminski, Alexander; Haydu, Lauren; Kefford, Richard (Rick); Long, Georgina; Lyle, Megan; Menzies, Alexander Maxwel; Azer, Mary W. F.; Klein, Oliver; Northern Clinical School: Melanoma Institute of Australia; Western Clinical School: Medicine (Westmead); Medicine Faculty Office; Central Clinical School: Surgery; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Central Clinical School: MedicineThe nature and management of metastatic melanoma after progression on braf inhibitors: Effects of extended BRAF inhibition, Cancer, vol.120, 20, 2014,pp 3142-3153